In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Falsified medicines Directive – Clarification on decommissioning of medical samples, IMP products and MNP products

Falsified medicines Directive – Clarification on decommissioning of medical samples, IMP products and MNP products

by In2Pharma | Apr 15, 2021 | News

Belgium The question was raised by some of the members whether it is needed to decommission commercial packages during (re)-labelling to medical samples, Medical Need Program (MNP) products and Investigational Medicinal Products (IMP).  After verification in the...

Recent Posts

  • Update instructions for distribution of DHPC in Luxembourg
  • Diploma for the Responsible Person for Information and Publicity (RIP)
  • Update Procedure for MA applications in Luxembourg
  • Labeling Medicinal products
  • New clarification about Day 0 in local literature search published by EMA

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België